About Plan A
Plan A is a Healthcare company based in San Luis Obispo (United States) founded in 2023. It operates as a non-hormonal reversible male contraception is provided using hydrogel technology. It operates on a HealthTech model. Plan A has raised $2.5 million across 1 funding round from investors including Transform VC. Its chief executive is L. R Fox. Its website planaformen.com draws about 16 thousand monthly visits. Plan A offers products and services including Plan A. Its focus areas include Biotechnology and Reproductive Health. Its legal entity is NEXT Life Sciences, Inc. Its competitors include Contraline, VasDeBlock, Ronikja and Bimek SLV; 2 of its 4 listed competitors have raised funding.
Company details
A non-hormonal, long-lasting, and reversible male birth control option named Plan A is being developed by NEXT Life Sciences. Focus is placed on addressing the global need for diverse family planning options, reducing the burden on women. The solution is aimed at providing greater reproductive control for individuals and couples. Research and clinical trials are conducted in regions like the US, UK, Australia, and New Zealand. The healthcare sector, specifically reproductive health, is targeted with innovative approaches to contraception.
- Headquarters San Luis Obispo, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website planaformen.com
- Social LinkedIn X Facebook Instagram
- Legal Name Next Life Sciences, Inc.
- Total Equity Funding$2.5M (USD)
in 1 rounds
- Latest Funding Round$2.5M (USD), Seed
Jan 2024
- Investors
Products & Services of Plan A
Plan A offers a comprehensive portfolio of products and services, including Plan A.
A non-hormonal, reversible male birth control option.
Funding Insights of Plan A
Plan A has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 1
- Last Round Seed — $2.5M
- First Round $2.5M
(Jan 2024)
- Investors Count 1
All 1 funding rounds of Plan A with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $2.5M | Seed | – | Transform VC | – |
1 investors in total: 1 institutional.
Investors in Plan A
Plan A has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Transform VC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage technology companies are funded by Transform VC. | – | transform.vc | San Francisco, United States |
Investor details for Plan A
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Plan A
1 people are tracked at Plan A (1 in leadership).
| Name | Role | Group |
|---|---|---|
L. R Fox | CEO | Leadership |
Complete people profiles for Plan A
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Plan A
2 dated milestones of Plan A across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Plan A is founded.
- Funding First funding round of $2.5M.
Competitors of Plan A
Plan A has 4 listed competitors in our database, 2 of them funded. They include Contraline, VasDeBlock, Ronikja and Bimek SLV, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| contraline.com | 2015 | Charlottesville, United States | $18.62M | 7 | Contraline is focused on developing innovative male contraception solutions. | |
| vasdeblock.com | 2016 | Karise, Denmark | $86,389 | – | Non-surgical reversible male contraception is developed by VasDeBlock. | |
| ronikja.com | 2020 | Reiskirchen, Germany | – | – | Develops heat-based male contraception device and seeks crowdfunding support. | |
| bimek.com | 1998 | Stuttgart, Germany | – | 3 | Develops a spermatic duct valve for male contraception. |
Detailed competitors of Plan A
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Plan A
The website of Plan A (planaformen.com) receives about 16.1K visits a month.
- Monthly visits16.1K
▲ 17.9% vs previous month
Websites whose visitors overlap most with Plan A. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mddionline.com | mddionline.com | 100% | – | #495,326 | – |
| parsemus.org | 96% | – | #1,251,334 | View details | |
| whitefoxdefense.com | 29% | 3.5K | #4,968,880 | View details |
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as Plan A (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Plan A
Plan A was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Plan A is headquartered in San Luis Obispo, United States. It is registered at San Luis Obispo, California, United States.
L. R Fox is the current CEO of Plan A.
Plan A is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on Jan 2024.
A non-hormonal, long-lasting, and reversible male birth control option named Plan A is being developed by NEXT Life Sciences. Focus is placed on addressing the global need for diverse family planning options, reducing the burden on women. The solution is aimed at providing greater reproductive control for individuals and couples. Research and clinical trials are conducted in regions like the US, UK, Australia, and New Zealand. The healthcare sector, specifically reproductive health, is targeted with innovative approaches to contraception.
Plan A's top competitors include Contraline, VasDeBlock and Ronikja.
Plan A offers Plan A.
Plan A has 1 investor. Key investors include Transform VC.
Plan A operates through Next Life Sciences, Inc..